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Abstract 
Background 
Bacteria employ complex transcriptional networks involving multiple genes in response to 
stress, which is not limited to gene and protein networks but now includes small RNAs 
(sRNAs). These regulatory RNA molecules are increasingly shown to be able to initiate 
regulatory cascades and modulate the expression of multiple genes that are involved in or 
required for survival under environmental challenge. Despite mounting evidence for the 
importance of sRNAs in stress response, their role upon antibiotic exposure remains 
unknown. In this study, we sought to determine firstly, whether differential expression of 
sRNAs occurs upon antibiotic exposure and secondly, whether these sRNAs could be 
attributed to microbial tolerance to antibiotics. 
Results 
A small scale sRNA cloning strategy of Salmonella enterica serovar Typhimurium SL1344 
challenged with half the minimal inhibitory concentration of tigecycline identified four 
sRNAs (sYJ5, sYJ20, sYJ75 and sYJ118) which were reproducibly upregulated in the 
presence of either tigecycline or tetracycline. The coding sequences of the four sRNAs were 
found to be conserved across a number of species. Genome analysis found that sYJ5 and 
sYJ118 mapped between the 16S and 23S rRNA encoding genes. sYJ20 (also known as 
SroA) is encoded upstream of the tbpAyabKyabJ operon and is classed as a riboswitch, whilst 
its role in antibiotic stress-response appears independent of its riboswitch function. sYJ75 is 
encoded between genes that are involved in enterobactin transport and metabolism. 
Additionally we find that the genetic deletion of sYJ20 rendered a reduced viability 
phenotype in the presence of tigecycline, which was recovered when complemented. The 
upregulation of some of these sRNAs were also observed when S. Typhimurium was 
challenged by ampicillin (sYJ5, 75 and 118); or when Klebsiella pneumoniae was challenged 
by tigecycline (sYJ20 and 118). 
Conclusions 
Small RNAs are overexpressed as a result of antibiotic exposure in S. Typhimurium where 
the same molecules are upregulated in a related species or after exposure to different 
antibiotics. sYJ20, a riboswitch, appears to possess a trans-regulatory sRNA role in antibiotic 
tolerance. These findings imply that the sRNA mediated response is a component of the 
bacterial response to antibiotic challenge. 
Background 
Multiple studies demonstrate that non coding RNAs (or small RNAs (sRNAs)) possess 
regulatory roles in the bacterial stress response [1-4]. Bacterial sRNA regulators typically 
range from 50 – 250 nts and are often transcribed from intergenic regions (IGRs), although 
open reading frames may also encode sRNAs [5]. Most sRNAs act as regulators at the post-
transcriptional level by base-pairing with target mRNAs; these sRNA-mRNA binding regions 
are often short and imperfect and may require an additional RNA chaperone, which in most 
cases is the Hfq protein [6,7]. This imperfect binding allows each sRNA molecule to control 
multiple targets [8], where either the translation of the target mRNA is upregulated, or more 
commonly inhibited. 
Many sRNA regulators are upregulated when bacteria sense environmental stress: these 
include oxidative stress [1], low pH environment [2], nutrient deprivation [4] and glucose-
phosphate stress [3]. Despite overwhelming evidence that sRNAs play a role when bacteria 
experience physiological stress, no systematic study has been undertaken to ascertain the 
impact or levels of sRNA production in bacteria when antibiotics are present. 
Naturally susceptible pathogens can develop drug resistance when treated with antibiotics [9]. 
Genetically acquired antibiotic resistance in pathogenic bacteria, via spontaneous / random 
mutations and horizontal gene transfer, is a significant issue in the treatment of infectious 
diseases [10]. Intrinsic regulatory networks such as those mediated by the transcriptional 
regulators MarA, SoxS and RamA are also implicated in the development of antibiotic 
resistance particularly since these systems control the influx / efflux of antibiotics [11]. Thus 
far studies that have focused on the intrinsic antibiotic resistome are limited to gene and 
protein networks mediated by these gene operons or other transcription factors [11-13]. 
Hence the role of the newly uncovered class of regulatory molecules such as sRNAs in 
controlling or contributing to the antimicrobial resistance phenotype is largely unknown. 
Some evidence for the role of sRNAs in mediating antimicrobial resistance already exists: for 
example, the expression of bacterial outer membrane proteins, OmpF and OmpC, involved in 
antibiotic import, is controlled by the sRNAs MicF and MicC respectively [14-16]. 
Additionally, the overexpression of another sRNA (DsrA) was recently found to induce 
multidrug resistance in Escherichia coli via the MdtEF efflux pump [17]. Nevertheless, 
whether the functional role of MicF, MicC and DsrA is indeed part of the bacteria’s intrinsic 
stress response to antibiotic challenge remains unknown. 
Tigecycline is a member of the glycylcycline group of antibiotics, and was registered in the 
EU in April 2006 [18]. This bacteriostatic antibiotic acts as a protein synthesis inhibitor by 
binding to the 30S ribosomal subunit [19]. Tigecycline is active against a broad range of 
bacteria, with only few naturally resistant exceptions, namely, Proteus spp., Morganella 
morganii, Providencia spp., and Pseudomonas aeruginosa. Specifically, tigecycline is 
effective against multidrug resistant bacteria such as Staphylococcus aureus (MRSA), 
vancomycin-resistant Enterococcus (VRE), extended-spectrum beta-lactamase (ESBL)-
expressing Enterobacteriaceae, and carbapenem-resistant strains [20-22]. Reports of 
resistance to tigecycline have been rare in naturally susceptible pathogens, however in 
resistant variants efflux pump overexpression has contributed to tigecycline resistance [23-
28]. 
Salmonella, a member of Enterobacteriaceae, encodes both the ramA transcriptional factor 
and the acrAB efflux pump, which when overexpressed confers tigecycline resistance [29]. 
Additionally, Salmonella represents a model bacterium for sRNA mining [30] and genome 
manipulation [29], making it an ideal system for our study, but more importantly represents a 
paradigm for other members of Enterobacteriaceae. Hence in this study we used a cloning 
strategy to determine the sRNA population after tigecycline exposure in Salmonella enterica 
serovar Typhimurium, and also whether the absence of these sRNAs would render the cells 
less adaptable to tigecycline challenge. 
Results 
cDNA library construction and analysis 
A cDNA library was constructed from the cells that were challenged by half the minimal 
inhibitory concentration (MIC) of tigecycline (0.125 μg/ml) at OD600 = 0.6. Approximately 
~6000 clones were obtained; from these 200 random candidates were sequenced and 
analysed. The nature of the cDNA library construction procedure (see Materials and 
Methods) allowed us to obtain the sequences in an orientation specific manner. The cDNA 
sequences were mapped to the S. Typhimurium SL1344 genome (FQ312003) using BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Of the mapped sequences, 31% encoded tRNAs; 6% 
and 9% matched to rRNAs and protein coding sequences, respectively; 4% partially 
overlapped with open reading frames (ORFs), and 50% aligned to IGRs. Of all the IGR 
readings, 90% were located between the 16S and 23S rRNA encoding genes (Figure 1). 
Figure 1 A pie chart representation illustrating the cDNA sequences distribution 
pattern on the SL1344 chromosome. The results showed that 50% of the sequences are 
encoded within IGRs, 90% of which are situated between 16S and 23S rRNA (shown on the 
right), 31% are tRNA sequences, 6% are part of rRNA sequences, 9% completely overlap 
with ORFs, and 4% partially overlap with ORFs 
Analyses of the cDNA sequences encoding partial ORFs indicated which genes were 
expressed in the presence of tigecycline. As stated above, 9% of the sequences identified 
matched to rRNAs, in addition to a further sequence which was found to overlap the 30S 
ribosomal protein and another mapped to elongation factor tu. This is perhaps not surprising, 
given that the specific target for tigecycline is the ribosome [19]. On the other hand, 
sequences overlapping known stress-response genes were also captured in the cDNA library, 
e.g. dinF and a gene encoding a putative outer membrane protein (SL1344_1151). The dinF 
gene is a member of the SOS response family and encodes an efflux pump which belongs to 
the multidrug and toxic compound extrusion (MATE) family [31], and SL1344_1151, 
encoding a putative outer membrane protein homologous to ycfR in E. coli, which influences 
biofilm formation through stress response and surface hydrophobicity [32]. The expression of 
these genes supports our hypothesis that challenge at half the MIC of tigecycline triggers a 
stress response. Of note, the cDNA library also contained sequences of different lengths that 
mapped to open reading frames, which we postulate to be a result of mRNA degradation, 
rather than a representation of bona fide sRNA regulators. Meanwhile, 4% of all sequences 
that partially overlap ORFs, all do so at the 5’ end of the ORFs. This suggests that these 
sequences might be 5’ untranslated regions, or encode riboswitches and / or control the 
expression of the downstream genes. 
Northern blot verification 
Northern blot analysis was performed on RNA extracted from SL1344 that were either 
unchallenged or challenged with half the MIC of tigecycline. Since most sRNAs are 
produced from IGRs [30], only sequences from these regions (100 out of 200 in total) were 
selected for further validation by northern blot analysis. As 90% of the IGR sequences are 
located between 16S and 23S rRNA coding sequences, most of which are identical, there 
were 20 unique IGR sequences (including those located between 16S and 23S rRNA) that 
were assayed, of which four (encoding sYJ5, sYJ20, sYJ75 and sYJ118) were found to 
consistently show elevated expression with tigecycline challenge (Figure 2A). The remaining 
sRNA candidates were either not detectable by northern blots, or did not show differential 
levels of transcription. Correspondingly all further analyses focused on these four sRNAs. 
The relative fold increase in sRNA expression was determined by northern blots in 
challenged versus unchallenged cells. Upon tigecycline exposure, the expression levels of 
sYJ5, sYJ20, sYJ75 and sYJ118 (performed in triplicate using densitometric analyses), 
relative to unchallenged cells, were increased to 8, 2, 2 and 8 fold, respectively (Figure 2A 
and B). We also tested the level of the four sRNAs in cells challenged with half the MIC of 
tetracycline (1 μg/ml). As expected, all of the four sRNAs were also found to be upregulated 
compared to the control sample (Figure 3A). This is possibly due to the fact that tigecycline 
and tetracycline are related compounds, and they may as well trigger stress response 
pathways that share a common set of regulatory molecules. Of note and as shown in Figure 
4A, the level of 5S RNA was not affected by the presence of half the MIC of tigecycline or 
tetracycline (5Stigecycline: 5Scontrol = 0.88, 5Stetracycline : 5Scontrol = 1.15, average of 4 different 
experiments). 
Figure 2 (A) Northern blot analysis for the four sRNAs (sYJ5, sYJ20 (SroA), sYJ75 and 
sYJ118) that were upregulated in the presence of tigecycline, and (B) bar chart 
illustration of the overexpressed sRNAs and (C) chromosomal locations and the 
directions of transcription of sYJ5, sYJ20, sYJ75 and sYJ118. A) Northern blot analysis 
for sYJ5, 20, 75 and 118. Image on top: all lanes marked by - were loaded with SL1344 total 
RNA extracted from cells grown under normal conditions (RDM, shaking, 37°C); all lanes 
marked by + were loaded with SL1344 total RNA extracted from cells challenged with half 
the MIC of tigecycline (0.125 μg/ml). Image below: representative image of the internal 
reference of 5S RNA levels in the same RNA samples. B) Densitometric analysis of the data 
from northern blot experiments of challenged / unchallenged cells with half the MIC of 
tigecycline. After normalisation to the 5S RNA levels, relative fold increases for sYJ5, 20, 75 
and 118 were found to be 8, 2, 2, and 8 fold, respectively compared to unchallenged cells. 
Error bars are generated based on three independent experiments. C) The three coding 
sequences of sYJ5 are located in (1) SL1344_rRNA0001-rRNA0002, (2) 
SL1344_rRNA0014-rRNA0015 and (3) SL1344_rRNA0017-rRNA0018. The two identical 
copies of sYJ118 are encoded in (1) SL1344_rRNA0010-rRNA0009 and (2) 
SL1344_rRNA0011-rRNA0012, and the other five paralogs are found in (1) 
SL1344_rRNA0001-rRNA0002, (2) SL1344_rRNA0006-rRNA0005, (3) 
SL1344_rRNA0014-rRNA0015, (4) SL1344_rRNA0017-rRNA0018 and (5) 
SL1344_rRNA0020-rRNA0021 
Figure 3 Northern blots for sYJ5, sYJ20 (SroA), sYJ75 and sYJ118 A) in SL1344 
challenged with half the MIC of tetracycline, B) ciprofloxacin or ampicillin, and the 
four sRNAs level in E. coli and K. pneumoniae challenged with half the MIC of 
tigecycline. A) Lanes marked by - were loaded with the control samples; lanes marked 
by + were loaded with total RNA extracted from cells that were challenged with half the MIC 
of tetracycline (1 μg/ml). The picture is composite from different experiments. B) Lanes 
marked by - (lane 1, 8, 15 and 18) were loaded with the control total RNA extracted from S. 
Typhimurium. Lanes marked by C (lane 2, 9, 16 and 19) were loaded with the total RNA 
extracted from S. Typhimurium that was challenged with half the MIC of ciprofloxacin 
(0.0156 μg/ml). Lanes marked by A (lane 3, 10, 17 and 20) were loaded with the total RNA 
extracted from S. Typhimurium that was challenged with half the MIC of ampicillin (1 
μg/ml). Lanes marked by K- (lane 4, 11 and 21) were loaded with the control total RNA 
extracted from K. pneumoniae. Lanes marked by K + (lane 5, 12 and 22) were loaded with the 
total RNA extracted from K. pneumoniae that was challenged with half the MIC of 
tigecycline (0.125 μg/ml). Lanes marked by E- (lane 6, 13 and 23) were loaded with the 
control total RNA extracted from E. coli. Lanes marked by E + (lane 7, 14 and 24) were 
loaded with the total RNA extracted from E. coli that was challenged with half the MIC of 
tigecycline (0.0313 μg/ml). Probe sequences were checked for 100% identity match in K. 
pneumoniae and E. coli prior to use 
Figure 4 Northern blots for A) the 5S RNA level in SL1344 and B) sYJ20 level in 
SL1344 and the ∆hfq strain (JVS-0255) in the presence of ciprofloxacin. A) Lane 1 and 3 
(also labelled as -) were loaded with SL1344 total RNA extracted from cells grown under 
normal conditions (RDM, shaking, 37°C); lane 2 was loaded with SL1344 total RNA 
extracted from cells challenged with half the MIC of tigecycline (0.125 μg/ml); lane 4 was 
loaded with SL1344 total RNFA extracted from cells challenged with half the MIC of 
tetracycline (1 μg/ml). All lanes were loaded with 125 ng of total RNA. The experiment was 
repeated 4 times. Densitometric analysis of the results showed little or no difference in 5S 
RNA expression level in the three growing conditions (5Stigecycline: 5Scontrol = 0.88, 5Stetracycline : 
5Scontrol = 1.15, average of 4 different experiments). B) Both strains (SL1344 and the hfq 
deletion strain (JVS-0255, Table 2)) were challenged with sub-inhibitory concentration of 
ciprofloxacin (0.0078 μg/ml) before the total RNA was extracted and probed for sYJ20 by 
northern blot. As shown above, the ∆hfq strain (right lane) produced less sYJ20 compared to 
SL1344 (left lane). 5S RNA was used as a loading control 
Bioinformatic analysis 
All four sRNA sequences were searched against S. Typhimurium SL1344 using NCBI 
BLAST. The sYJ5 encoding sequence is located between the 16S (SL1344_rRNA0001) and 
23S rRNA (SL1344_rRNA0002) coding loci on the sense strand (Figure 2C (i)). BLAST 
analysis uncovered two additional identical copies in the genome sequence of SL1344 (one 
between SL1344_rRNA0014 and SL1344_rRNA0015, the other SL1344_rRNA0017 and 
SL1344_rRNA0018). 
Similar to sYJ5, sYJ118 is also encoded from the IGR between the 16S and 23S rRNA 
coding sequences, but from a different genetic locus (SL1344_rRNA0009 – 
SL1344_rRNA0010, Figure 2C (iv)). The sequence encoding sYJ118 has an identical copy 
(SL1344_rRNA0011 – SL1344_rRNA0012) and additionally five other paralogs with 93% - 
99% identity on the SL1344 chromosome. 
The encoding sequence of sYJ75 is flanked by entC downstream (encoding isochorismate 
synthase), and fepB upstream (encoding the iron-enterobactin transporter periplasmic binding 
protein) (Figure 2C (iii)). It also has a paralog that shares 90% identity, starting at position 
1515629 on the S. Typhimurium SL1344 genome and located between pntB (encoding 
pyridine nucleotide transhydrogenase β subunit) and an un-annotated gene (encoding a 
putative membrane protein). 
sYJ20 was previously identified by Vogel et al. in E. coli as SroA [5], encoded by a sequence 
downstream of yabN (encoding SgrR, a transcriptional regulator in E. coli [33]) and upstream 
of tbpA (encoding the thiamine-binding periplasmic protein, homologous to thiB in E. coli) 
(Figures 2C (ii) and 5A). 
Figure 5 The chromosomal location of the sYJ20 (SroA) encoding region and its 
encoding sequence. sYJ20 is encoded upstream of the tbpA-yabK-yabJ operon, and the 
shared TSS of sYJ20 and tbpA as determined by 5’ RACE analysis is represented by the 
dark-black arrow. The DNA sequence of sYJ20 (SroA) is shown in bold letters, which is also 
the region that was deleted in YJ104 and used for TargetRNA prediction (Table 1). The THI-
box sequence is underlined. The start codon of tbpA is displayed at larger size as GTG, where 
the first G is considered +1 in the numbering system 
sYJ5, sYJ20 (SroA) and sYJ118 are all highly conserved within the different members of 
Enterobacteriaceae, although the coding sequences of sYJ5, sYJ20 and sYJ118 are also found 
in other families of bacteria (such as sYJ5 and sYJ118 in Prevotella ruminicola, sYJ20 in 
Marinobacter aquaeolei VT8), in plants (such as sYJ20 and sYJ118 in Zea mays cultivar line 
T63) and in animals (sYJ118 in Gryllus bimaculatus). In contrast, sYJ75 is only found in 
Salmonella, Enterobacter, Photorhabdus and Citrobacter. 
sYJ20 (SroA), sYJ5, sYJ75 and sYJ118 in other species and relevance to other 
drug classes 
We proceeded to determine whether the increased expression of these sRNAs would be 
Salmonella specific or drug-class specific. Hence, we assessed the levels of our sRNA 
candidates (sYJ5, sYJ20 and sYJ118) in other members of Enterobacteriaceae (Klebsiella 
pneumoniae and Escherichia coli) when challenged with sub-inhibitory levels of tigecycline 
(sYJ75 was not included since it is not encoded in the tested species). Additionally, in order 
to determine whether these sRNAs are upregulated solely as a result of tigecycline challenge 
or are generally upregulated as a result of sub-inhibitory antibiotic challenge, S. 
Typhimurium SL1344 was challenged with either half the MIC of ampicillin (1 μg/ml) or 
ciprofloxacin (0.0156 μg/ml). As shown in Figure 3B, none of the four tested sRNAs were 
upregulated in response to ciprofloxacin exposure, whilst three (sYJ5, sYJ75 and sYJ118) 
were found to be upregulated in the presence of ampicillin. Interestingly, E. coli did not 
upregulate the expression of the three candidate sRNAs (sYJ5, sYJ20 and sYJ118) in 
response to challenge at half the MIC of tigecycline. However, sYJ118 exhibited an elevated 
level of expression in K. pneumoniae in the presence of tigecycline (Figure 3B). Of note, 
although the sYJ20 (SroA) coding sequence is present in K. pneumoniae, two transcripts 
were detected after hybridisation. However it was the larger RNA species that appeared 
upregulated in RNA derived from Klebsiella cells challenged with half the MIC of 
tigecycline. Hence we surmise that this larger RNA transcript, consistent with the larger 
intergenic region in K. pneumoniae, is where the sYJ20 homolog coding sequence is located. 
From these results we show that the upregulation of sRNAs identified in this study are neither 
species nor drug specific in the presence of unrelated classes of antibiotics. 
5’ Rapid Amplifed cDNA Ends (5’ RACE) of sYJ20 (SroA) 
To determine the transcriptional start site (TSS) of sYJ20 (shared with the one of tbpA), we 
performed 5’ RACE analysis. As shown in Figure 5, the 5’ RACE result reveals that the TSS 
of sYJ20 and tbpA lies 129 bases upstream of the start codon of tbpA, consistent with 
previous findings [34]. 
Quantitative Real Time PCR (qPCR) 
sYJ20 (SroA): the upregulation of sYJ20 in S. Typhimurium challenged by half the MIC of 
tigecycline or tetracycline was quantified with qPCR. As shown in Figure 6, compared to the 
control, cells challenged by tigecycline or tetracycline produced ~3 fold more sYJ20. 
Interestingly, the transcription level of the downstream gene, tbpA, was hardly affected by the 
presence of the antibiotics. This suggests that sYJ20, but not the tbpA gene product, is 
upregulated as a result of tigecycline or tetracycline challenge. 
Figure 6 qPCR on sYJ20, tbpA and stress responsive genes (dinF and ycfR) on SL1344 
control (no challenge with antibiotics), SL1344 challenged with half the MIC of 
tigecycline (0.125 μg/ml), and SL1344 challenged with half the MIC of tetracycline (1 
μg/ml). QPCR was performed as described in Materials and Methods. All the fold changes 
are calculated relative to the value of the control (SL1344, unchallenged). Error bars are 
generated from at least 4 experiments 
dinF (encoding an efflux pump) and ycfR (encoding a putative outer membrane protein): as 
mentioned previously, the RNA transcripts of these two stress responsive genes were picked 
up in the sRNA cloning and is suggestive that half the MIC of tigecycline does induce a 
stress response in S. Typhimurium. In order to confirm this, we performed a qPCR on S. 
Typhimurium challenged by half the MIC of tigecycline or tetracycline, and compared the 
transcriptional levels of dinF and ycfR to the control. As shown in Figure 6, the 
transcriptional level of dinF increased to 7.0 and 2.8 fold when the cells were challenged by 
half the MIC of tigecycline and tetracycline, respectively; the level of ycfR increased to 390 
and 210 fold when the cells were challenged by half the MIC of tigecycline and tetracycline, 
respectively. 
Survival rate assays 
Survival rate assays were performed to investigate whether the deletion of sYJ20 (SroA) 
would highlight any phenotypic deficiencies when challenged with tigecycline. Our initial 
tests showed that the MICs of the mutant (YJ104) and the wild type strains (SL1344) were 
identical to tigecycline (MIC: 0.25 μg/ml in RDM). We then performed growth curves in 
RDM, where both SL1344 and YJ104 exhibited similar growth rates, as determined by OD600 
readings, even in the presence of tigecycline (data not shown). 
To determine whether sYJ20 confers an advantage to bacterial survival in the presence of 
tigecycline challenge, the survival frequencies were determined for the wild type SL1344 and 
YJ104 in the presence of 1 ×, 2 ×, 4 × and 8 × MIC of tigecycline. Both SL1344 and YJ104 
failed to form any colonies on 2 ×, 4 × and 8 × MIC plates after overnight incubation at 37°C. 
The survival rates for SL1344 and YJ104 at 1 × the MIC were ~2.1 × 10-7 and 1.1 × 10-7 
respectively (Figure 7). Despite this modest decrease, statistical analysis on four biological 
replicate experiments supports that the reduced survival rate observed in YJ104 is indeed 
significant (P < 0.05). The survival rate was restored upon complementation where YJ107 
(YJ104/pACYC177•sYJ20) yielded a survival frequency close but higher than SL1344 
(2.1 × 10-7, Figure 7), and as expected the plasmid control YJ110 (YJ104/pACYC177) had a 
similar survival rate to YJ104 (1.0 × 10-7, Figure 7). This reduction in the survival rate of 
YJ110 compared to the one of YJ107 was also found to be statistically significant (P < 0.05). 
Overall, it suggests that the absence of sYJ20 could confer a subtle but reduced survival rate 
in the presence of tigecycline. 
Figure 7 Survival rate assays of SL1344, YJ104, YJ107 and YJ110 when cells were 
challenged with MIC of tigecycline. Fresh overnight culture was spread on RDM plates 
either supplemented with MIC of tigecycline (0.25 μg/ml) or nothing (as a control). Colony 
number was determined after overnight incubation at 37°C. Survival rate was calculated as 
follows: cfu/ml on the tigecycline plate divided by cfu/ml on the control plate. P values were 
also calculated from at least three biological replicates. We found that statistical comparisons 
of SL1344 versus YJ104 (∆sYJ20) and YJ107 (YJ104/pACYC177•sYJ20) versus YJ110 
(YJ104/pACYC177) are significant (P < 0.05) 
Discussion 
Small RNAs are regulatory molecules that enhance a bacterium’s adaptability in a constantly 
changing environment [1-4]. As regulatory molecules, sRNAs have several advantages over 
their protein counterparts. Firstly, sRNAs consist of a short nucleotide sequence which does 
not require translation into a peptide sequence. This ensures that the response from sRNA 
mediated regulators would be much more rapid than protein mediated factors [35]. 
Accordingly, modelling studies suggest that due to the rapid kinetics associated with sRNA 
production, the downstream regulon response is correspondingly prompt when compared to 
protein based factors, a valuable trait in constantly evolving environments [35]. Moreover, 
base pairing flexibility presumably allows rapid evolution of sRNAs [35]. Finally, sRNA-
mRNA interaction generally lacks specificity and often imperfect binding occurs ensuring 
that more than one target mRNA is affected, thereby expanding the repertoire of the sRNA 
regulators [8]. At antibiotic concentrations at or higher than the MIC, cells are likely to halt 
cellular replication and / or stop growing, or result in the accumulation of advantageous 
genomic mutations [36], which may permanently alter the transcriptional profiles of bacteria 
[37]. Hence we surmised that the sRNAs upregulated in the cells under these conditions may 
not be a direct result of antibiotic stress response but possibly due to genetic mutations or 
global perturbations. Therefore, a cDNA library was constructed from the cells that were 
challenged by half the MIC of tigecycline at mid-log phase. 
In support of our hypothesis, our screen identified genes involved in the stress response when 
the bacterial cells were challenged with half the MIC of tigecycline. These include a SOS 
response gene, dinF, encoding a MATE family efflux pump, and a gene homologous to ycfR 
in E. coli, encoding a putative outer membrane protein. QPCR confirms the upregulation of 
the two genes when S. Typhimurium is challenged with half the MIC of tigecycline or 
tetracycline (Figure 6). Our finding of four sRNAs (sYJ20 (SroA), sYJ5, sYJ75 and sYJ118) 
that are upregulated in the presence of tigecycline or tetracycline provides the first direct 
evidence that sRNAs are differentially expressed upon antibiotic exposure. It is known that 
tetracycline triggers mRNA accumulation in bacteria [38]. However, this is unlikely to be the 
case as increased transcription was not noted for e.g. tbpA (open reading frame lying 
downstream of sYJ20, Figure 6), and the gene encoding the 5S RNA (Figure 4A). 
Two of the four sRNAs (sYJ5 and sYJ75) we describe in this study are novel. Additionally, 
our work shows that these four sRNAs are not species specific as both sYJ20 and sYJ118 are 
upregulated in K. pneumoniae when challenged with half the MIC of tigecycline, or drug 
specific as sYJ5, sYJ75 and sYJ118 are upregulated as a result of ampicillin challenge 
(Figure 3B). Both sYJ118, previously identified as StyR-44 in Salmonella [39], and sYJ5, a 
novel sRNA discovered in this study, are located between 16S and 23S rRNA coding 
sequences (Figure 2C). 
Both tigecycline and tetracycline target the 30S ribosomal subunit in bacterial cells. This 
might trigger over-production of the 16S-23S rRNA molecules, which also includes sYJ5 and 
sYJ118. This may raise the possibility that sYJ5 and sYJ118 are “by-products” rather than 
bona fide sRNA regulators. However, in support of sYJ5 and sYJ118 being classed as 
sRNAs, not all 16S-23S rRNA intergenic regions identified in our screen were upregulated in 
the presence of tigecycline when assessed by northern blots (data not shown). Furthermore, 
only sYJ118, not sYJ5, was upregulated in K. pneumoniae when challenged with tigecycline 
(Figure 3B). Taken together these data lead to the observation that these different inter 16S-
23S rRNA regions (including the regions encoding either sYJ5 or sYJ118) may have 
alternative functions independent of rRNA processing, which could be regulatory sRNA. 
In this work we have used the 5S RNA as a loading control for northern blot assays. Given 
that it is a ribosomal RNA we wondered whether the 5S RNA levels would be affected by 
either tigecycline or tetracycline exposure. As shown in Figure 4A, the 5S RNA expression 
levels were unaltered when the cells were challenged with half the MIC of tigecycline or 
tetracycline, and therefore it is a suitable loading control for the northern blot assays. 
The four sRNAs (sYJ5, sYJ20, sYJ75 and sYJ118) that were upregulated as a response to 
tigecycline challenge in S. Typhimurium were also upregulated in tetracycline challenged 
cells (Figures 2A and 3A). This is not surprising since both tigecycline and tetracycline target 
the 30S ribosomal subunit. It is possible that the similar mechanisms of action of tetracycline 
and tigecycline trigger comparable stress-responsive pathways, which possibly include sYJ5, 
sYJ20, sYJ75 and sYJ118. 
sYJ75 has not been previously described and thus is also a novel sRNA discovered in this 
study. Its conservation among several species and its upregulation in S. Typhimurium upon 
challenge with tigecycline and tetracycline, (Figures 2A, 3A) suggest that sYJ75, combined 
with its conservation across different species, may represent a common denominator in the 
response to tigecycline / tetracycline exposure. Interestingly, none of the four sRNAs were 
found upregulated when S. Typhimurium was exposed to ciprofloxacin, or when E. coli was 
challenged with tigecycline (Figure 3B). 
When challenged with tigecycline, both S. Typhimurium and K. pneumoniae upregulated two 
sRNAs, namely sYJ20 and sYJ118 (Figure 3B). Despite encoding these sequences, no 
upregulation was noted in E. coli cells exposed to tigecycline compared to the unexposed 
controls (Figure 3B). This suggests two possibilities: the first, where the tigecycline stress 
response involving sRNAs in E. coli is different from that in K. pneumoniae and S. 
Typhimurium, and the second, where the sRNAs (sYJ20 and sYJ118) may be linked to 
regulatory networks contributing to tigecycline resistance, i.e. RamA, only found in S. 
Typhimurium and K.pneumoniae but not in E. coli [40,41]. However TargetRNA [42] 
predictions for sYJ20 for cognate mRNA binding partners, using default parameters, yields 
four mRNA sequences (Table 1). Of note, pspB and pspA which are involved in stress-
response and the virulence attributes of several bacterial species [43] are potential targets of 
sYJ20. sYJ20-mediated control of the psp operon may explain the reduced fitness of the sroA 
(sYJ20) deleted Salmonella strain in a mouse infection model [44]. 
Table 1 TargetRNA predictions for sYJ20 
Rank Gene Synonym Score p-value sRNA 
start 
sRNA 
stop 
mRNA 
start 
mRNA 
stop 
1 pspB STM1689 −60 0.00598756 17 28 9 −3 
2 nrdI STM2806 −60 0.00598756 17 28 9 −3 
3 STM0269 STM0269 −59 0.00721216 7 29 16 −4 
4 pspA STM1690 −59 0.00721216 35 60 14 −10 
The sequence of sYJ20 (as shown in Figure 5, bold letters) was applied as the input for 
TargetRNA (http://snowwhite.wellesley.edu/targetRNA/) prediction with default parameters 
A recent study undertaken to map sRNA profiles in SL1344 using massive parallel 
sequencing technology identified 140 sRNAs. Notably, sYJ5 and sYJ75 were not identified 
in this large scale study which suggests that firstly, these sRNAs are produced as a result of 
conditional exposure e.g. tigecycline and secondly that our small scale screen is able to 
uncover novel sRNAs [34]. The encoding sequences of three sRNAs (sYJ5, sYJ75 and 
sYJ118) identified in this screen have more than one paralog within S. Typhimurium’s 
genome, making it difficult to pinpoint their exact roles in the bacterial response against 
antibiotic challenge through genetic analysis. Due to this reason, only sYJ20 and its 
associated phenotype were investigated further. 
sYJ20, also known as SroA [5], is encoded immediately upstream of the tbpAyabKyabJ 
operon (homologous to thiBPQ in E. coli) and contains a THI-box sequence required as a 
riboswitch for the modulation of the tbpAyabKyabJ operon (Figure 5). The deletion of the 
chromosomal sequence of sYJ20 would have very likely removed the TSS of the downstream 
gene tbpA (Figure 5). However, tbpA transcript levels remained unaltered upon tigecycline / 
tetracycline exposure (Figure 6). Therefore the polar effect of the sYJ20 deletion is 
considered to be minimal. 
When survival rate assays were performed a subtle but reproducible deficiency (P < 0.05) as 
reflected by a reduction in the viability in the ΔsYJ20 strain (YJ104) compared to the wild 
type strain (SL1344) (Figure 7) was observed. This deficiency was alleviated when a plasmid 
encoding allele of sYJ20 was transformed in YJ104 (i.e. YJ107), where the vector only 
control (i.e. YJ110) did not (Figure 7). This subtle change of phenotype is not entirely 
surprising, as it has been observed that sRNA deletions usually have little, if any, effect [45]. 
In fact, sYJ20, or SroA, has been linked to other phenotypes such as reduced fitness by a 
ΔsroA S. Typhimurium strain (sroA encodes sYJ20) during competitive infection with the 
wild type strain in mice [44]. However it is not evident from the work whether the reduction 
in competitiveness of the ΔsroA S. Typhimurium strain is due to altered tbpA expression. 
Previous work suggests that sYJ20 (SroA) may function as a riboswitch for the 
tbpAyabKyabJ (thiBPQ) operon [5] in E. coli and that this regulatory role does not require 
Hfq [46]. In our studies, we can show that the wild type strain S. Typhimurium (SL1344) 
produces sYJ20 (transcript size around 100 nts) in the presence of sub-inhibitory 
concentration of ciprofloxacin (0.0078 μg/ml) whilst the Δhfq strain [7] produced less (Figure 
4B). This suggests that sYJ20, apart from its putative riboswitch role, can act as a trans-
regulatory sRNA, as Hfq is typically required for functionality and stability by trans-encoded 
sRNAs [47]. This is further supported by the two facts that A) the mild defect due to the 
chromosomal deletion of sYJ20 in SL1344 can be complemented by the plasmid-coding 
allele (YJ107), which cannot be attributed to its role as riboswitch, since the RNA transcripts 
of sYJ20 (on plasmid) and tbpA (on chromosome) are on separate strands, and B) sYJ20 was 
upregulated in S. Typhimurium challenged with half the MIC of tigecycline or tetracycline, 
where the transcriptional level of tbpA remained the same (Figure 6). The transcript size of 
sYJ20, as detected by northern blot analysis, is approximately 100 nts which is consistent 
with the size reported in E. coli (93 nts) [5]. As has been suggested previously, it is possible 
that sYJ20 is generated by transcription attenuation of tbpAyabKyabJ [5]; and the released 
short sYJ20 (around 100 nts) functions as a sRNA by regulating alternative targets in trans in 
the cell. 
Conclusions 
Our work shows that sRNAs upregulated in response to tigecycline exposure can also be 
produced in a non drug or species specific manner. The deletion of the sRNA, sYJ20 (SroA) 
confers a subtle survival disadvantage in the presence of tigecycline, possibly due to its role 
as a trans-regulatory sRNA after tigecycline exposure. Our results although preliminary, 
suggest that sRNA levels can be altered upon antibiotic exposure and presumably provide an 
initial survival advantage under antibiotic challenge. However, ongoing analyses are required 
to dissect the regulatory impact(s) of sRNA upregulation and its contribution to antibiotic 
resistance in bacteria. 
Methods 
Growth conditions 
Bacteria were cultured in Rich Defined Medium (RDM: 1 × M9 salts, 0.4% glucose, 
1 × Essential Amino Acids (Gibco), 1 × Nonessential Amino Acids (Sigma-Aldrich, UK), 2 
mM MgCl2, 0.1 mM CaCl2) unless otherwise stated. Typically, a strain was grown on a 
Luria-Bertani (LB) plate from frozen stock prior to experimental manipulations. A 1 in 100 
dilution of fresh overnight culture was made in RDM and incubated in a 37°C shaker until 
OD600 reached 0.6, at which point half the MIC of the selected antibiotic (For SL1344: 
tigecycline (MIC = 0.25 μg/ml), tetracycline (MIC = 2 μg/ml), ciprofloxacin (MIC = 0.0312 
μg/ml), or ampicillin (MIC = 2 μg/ml), for K. pneumoniae: tigecycline (MIC = 0.25 μg/ml), 
for E. coli: tigecycline (MIC = 0.0625 μg/ml), for JVS-0255: ciprofloxacin (MIC = 0.0156 
μg/ml)) was added to the medium. The same volume of sterile water was added to another 
sample as a control. All strains used in this study are shown in Table 2. 
Table 2 Strains and plasmids used in this work 
Strain Genotype Comment 
SL1344 Salmonella enterica serovar 
Typhimurium wild type 
[48] 
JVS-0255 SL1344 ∆hfq [7] 
MG1655 Escherichia coli wild type [49] 
Ecl8 Klebsiella pneumoniae wild 
type 
[50] 
YJ104 SL1344 ∆sYJ20*::cat This work, derived from SL1344 
YJ107 SL1344 ∆sYJ20::cat pYJ104 This work, derived from YJ104 
YJ110 SL1344 ∆sYJ20::cat 
pACYC177 
This work, derived from YJ104 
Plasmid Genotype  
pACYC177   
pYJ104 pACYC177 •sYJ20 HindIII/BamHI fragment from PCR for SL1344 
using primers sYJ20_HF and sYJ20_BR 
*: sYJ20 is the coding sequence for SroA 
Minimum inhibitory concentration (MIC) determination 
The MICs of all relevant strains in RDM to tigecycline, (gift from Wyeth Pharmaceuticals, 
US), tetracycline (Sigma-Aldrich, UK), ciprofloxacin and ampicillin (Sigma-Aldrich, UK) 
were determined and interpreted according to the BSAC protocols [51]. In order to check 
whether concentrations at half the MIC would induce stress response rather than kill the cells 
in liquid medium, half of the MIC of the antibiotic was added to liquid culture at OD600 = 0.6 
(sterilised water was added to the control). After growth for an hour or overnight, an aliquot 
of the culture was taken and spread on plates, to determine colony forming unit per ml 
(cfu/ml). Additionally growth curves were also generated based on the OD600 readings. The 
stress response was confirmed by comparison of the antibiotic challenged cells to the control 
on both the growth curves and the cfu/ml. 
RNA extraction 
Cells were grown to OD600 = 0.6 prior to the addition of the antibiotic. After 1 hour of 
exposure, cells were harvested by centrifugation. The cell pellet was then resuspended in 
TRIzol reagent (Invitrogen) and the total RNA was extracted according to Santhakumar et al. 
[52]. The resulting pellet was washed and resuspended in an appropriate amount of DEPC 
(Sigma, UK) treated water. 
cDNA library construction 
The cDNA library was constructed (according to the manufacturer’s instruction) using the 
Exact START Small RNA Cloning kit from Epicentre (Cambio, UK). Briefly, total RNA was 
digested with DNase I to remove any contaminating DNA, and small RNAs were enriched 
with Epicentre enrichment solution by precipitating RNA molecules longer than 200 nts. The 
enriched RNAs were treated with phosphatase (Cambio, UK) to convert 5’ triphosphate 
group of RNA molecules to 5’ monophosphate, and a poly-A tail was added to the 3’ end 
(according to the manufacturer’s instruction). The 5’ end of RNA was ligated with Acceptor 
Oligo that carries a NotI restriction site. Reverse transcription was performed to yield first 
cDNA strand, using a primer with poly-T at its 3’ end to cover the poly-A tail of RNA 
samples, and an AscI restriction site. After RNase digestion, the sample was subject to a PCR 
with Small RNA PCR Primer 1 and 2. The product was digested by NotI and AscI (New 
England Biolabs) and was subsequently cloned into the cloning-ready pCDC1-K vector 
(Cambio, UK). Since the 5’ ligation adaptor differs from the 3’ ligation adaptor, the cloning 
of these putative small RNA molecules is directional. All oligonucleotides used in this study 
are listed in Table 3. 
Table 3 Oligos used in this work 
Name Sequence 5’-3’ Reference 
For deletion of sY20 in SL1344 
sYJ20_Cm_F 
CTTGATTGCTGCCCGGCAACAAAA
TCACTACACTAACGCCGTGTAGGC
TGGAGCTGCTTC 
This work 
sYJ20_Cm_R 
CTTTGCACCTCAGTTAAAGAGTGG
CAAAGGACTTGAGATGGGAATTAG
CCATGGTCC 
For cloning sYJ20 coding sequence onto pACYC177 
sYJ20_HF 
CCCAAGCTTCTTGATTGCTGCCCGG
CAACAA   
This work 
sYJ20_BR 
CGGGATCCCTTGAGAGGTAGCCTC
AAATCCCTT 
For the northern blot assays 
NsYJ5 AGGTTTTACTGCTCGTTTTTCA 
This work 
NsYJ20 ATCCGGATCAGGTTCGACGGGTAT 
NsYJ75 GCGGGGATTTCTTCCCTTGC 
NsYJ118 
TGTGTTTCAATTTTCAGCTTGATCC
AGATT 
5S CTACGGCGTTTCACTTCTGAGTTC [53] 
For qPCR 
16SF GTTACCCGCAGAAGAAGCAC 
This work 
16SR CTACGCATTTCACCGCTACA 
tbpAF GGCTGGAAAAACGACACATT 
tbpAR TAGACTTTGCGCATCCACAG 
ycfR-F TGCCGTACTGAGTTCGCTCT 
ycfR-R GGGCCGGTAACAGAGGTAAT 
dinF-F TTACTGGGGCTGGTCGATAC 
dinF-R GCCAGCAATAACGGTTGAAT 
q5S-F CATGCCGAACTCAGAAGTGA 
q5S-R AGTTCCCTACTCTCGCATGG 
For 5’RACE 
GSP1 GGCGAAATAGCCGTAAT 
This work GSP2 GGGCACCTTGACCGCTTCAT 
GSP3 GCCACGCCGCTTTTGGCAAA 
Northern blots 
Ten micrograms of total RNA was separated on 8% polyacrylamide gel containing 8 M urea, 
and electro-transferred onto Hybond-N nylon membrane (GE Healthcare). The membrane 
was hybridised and washed according to Vogel et al. [54], and exposed to a phosphor-imager 
(Fuji). Relative levels of increase in expression were determined by Multi Gauge 2.2 
(Fujifilm). The bands were first normalised to the 5S RNA levels prior to calculating the fold 
increase of challenged versus unchallenged cells. The oligonucleotide probes used in the 
northern blot experiments are listed in Table 3, and were end-labelled with γ32P-ATP using 
T4-polynucleotide kinase and purified prior to blot hybridisation. 
Chromosomal sYJ20 (SroA) inactivation 
The chromosomal inactivation of sYJ20 (SroA) was performed according to the manipulation 
strategy outlined by Datsenko and Wanner [55]. Briefly, primers (sYJ20_Cm_F and 
sYJ20_Cm_R, sequences listed in Table 3) with ~40 bases with 5’ end homology to the 
flanking regions of the sYJ20 coding sequence were used to amplify the cat locus on pKD3 
by PCR. The PCR product was transformed into S. Typhimurium SL1344 carrying the 
plasmid pKD46. The transformed cells were selected on LB plates supplemented with 
chloramphenicol. Colonies were picked after an overnight incubation and the replacement of 
the chromosomal sYJ20 coding sequence with the cat cassette was verified by PCR and 
sequencing. 
Quantitative Real Time PCR (qPCR) 
All the primers for qPCR were tested for amplification efficiencies prior to use. cDNA was 
made with SuperScript® VILO
TM
 cDNA Synthesis Kit (Invitrogen), which was then subject 
to qPCR with Platinum® SYBR® Green qPCR SuperMix-UDG (Invitrogen). The qPCR was 
performed using the Mx3005P qPCR system (Agilent/Strategene). Analyses of the QPCR 
data were undertaken using the MxPro algorithms (Agilent, UK) where the normalisation of 
the amplification data was to the 5S RNA levels. 
Complementation assay 
The sequence spanning 40 bases upstream and 6 bases downstream up to the sYJ20 sRNA 
encoding sequence was amplified with primers sYJ20-HF and sYJ20-BR and cloned into 
pACYC177. The recombinant plasmid carrying the sYJ20 encoding sequence was verified by 
sequencing before transformation into YJ104 (SL1344 ΔsYJ20) to yield YJ107. Empty 
pACYC177 was also transformed into YJ104 to yield YJ110, used as a negative control. The 
levels of sY20 expression were confirmed by northern blots. 
5’ RACE 
In order to determine the TSS of sYJ20 and tbpA, we employed the 5’ RACE System for 
Rapid Amplification of cDNA Ends (version 2.0, Invitrogen). Briefly, the first strand cDNA 
was produced using SuperScript
TM
 II Reverse Transcriptase (Invitrogen) with the GSP1 
primer specifically matching to the tbpA RNA transcript. Following purification with the 
S.N.A.P column (Invitrogen), the 5’ end of the first strand cDNA was tailed with multiple C 
(cytidines) with dCTP and TdT. A PCR was performed with the Abridged Anchor Primer 
(Invitrogen) that targets the dC-tailed 5’ cDNA end, and the GSP2 primer attaching to the 
RNA transcript upstream of the GSP1 matching region. A nested PCR was also performed to 
increase the specificity with the nested GSP3 primer and the AUAP primer (Invitrogen). The 
PCR product was ligated onto the pGEM-T EASY vector, and was sequenced with the T7 
Forward primer or the SP6 Reverse primer. 
Survival rate assay 
To assess the fitness of strains challenged with tigecycline, a survival rate assay of the wild 
type (SL1344), the ΔsYJ20 mutant (YJ104), the plasmid complemented strain (YJ107), and 
the vector only control (YJ110) was performed. One hundred microlitres of cells from fresh 
overnight RDM cultures were spread evenly on RDM plates supplemented with tigecycline at 
the MIC, 2 × MIC, 4 × MIC or 8 × MIC. The same batch of cells was also spread on RDM 
plates with no antibiotics to establish the baseline levels. 
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